Trial reportInternational journal of radiation oncology, biology, physics2026
A Phase 2 Exploratory Trial Evaluating Computed Tomography-Based Midtreatment Nodal Response to Select for De-escalated Chemoradiation Therapy in the Definitive Management of p16+ Oropharyngeal Cancer.
Trial report in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
purposeThis prospective, nonrandomized phase 2 single-arm pilot trial aimed to explore favorable midtreatment nodal response (FMNR) through computed tomography (CT) imaging to guide de-escalated chemoradiation therapy (CRT) in patients with favorable risk, node-positive human papillomavirus (HPV)-associated oropharyngeal cancer (OPC). METHODS AND MATERIALS: Eligible patients included p16+ OPC (AJCC 8th: cT1-3 N1 M0, <10 pack-year smokers). All patients were initially planned to receive 70 Gy with concurrent weekly cisplatin 40 mg/m
resultsOf 39 patients, 26 had FMNR and underwent de-escalated treatment. Thirteen patients had slow midtreatment nodal shrinkage and received a standard dose. At a median follow-up of 47.4 months, the 2-year PFS was 92.1% (95% CI, 0.72-0.98) for the de-escalated dose group and 92.3% for the standard dose patients (95% CI, 0.57-0.99), P = .96. With a median survival follow-up of 48.9 months (range, 16.7-77.8 months), there were no deaths or distant failures. FMNR was associated with rapid TTMV HPV DNA clearance, reduced TTMV HPV DNA flare, lower baseline and week 4 MRI diffusivity, and higher baseline and week 4 MRI diffusional kurtosis. No differences in acute or late maximum grade 3 to 4 toxicity by patient were noted. MD Anderson Dysphagia Inventory composite scores showed minimal clinically important difference in the de-escalated group at 1-month posttreatment, whereas the standard group had minimal clinically important difference up to 1-year posttreatment. No patients required feeding tube placement.
conclusionsDe-escalated CRT using CT-based midtreatment nodal response in favorable risk, node-positive HPV-associated OPC achieved excellent 2-year PFS and overall survival rates, and represents a potential approach in better selecting patients for treatment de-escalation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.